GlassScriptPhysician profile
Olivia A Mansilla
NPI 1376563189
$3,377.85
in general payments reported to CMS, 2019-2025
31 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $203 · 2021: $607 · 2022: $290 · 2023: $358 · 2024: $997 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $524.42 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $487.19 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $457.98 | 2021-2025 | |
| Amgen INC. | $310.86 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.11 | 2020-2025 | Xifaxan |
| Medicure Pharma INC. | $169.95 | 2019-2021 | |
| Eisai INC. | $151.92 | 2024-2025 | |
| Pfizer INC. | $120.18 | 2019-2024 | |
| Amarin Pharma, INC. | $118.08 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $107.09 | 2024-2025 | |
| Allergan, INC. | $91.43 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $70.14 | 2021 | |
| Avanir Pharmaceuticals, INC. | $56.96 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $49.20 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $44.03 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $39.53 | 2023 | Optimizer |
| Abbott Laboratories | $36.40 | 2021-2024 | Freestyle Libre 3 |
| Philips North America LLC | $35.48 | 2024 | (Ck6) Holter |
| Lumenis, INC | $34.24 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.72 | 2020-2025 | Breztri |
| Sun Pharmaceutical Industries INC. | $32.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.13 | 2022 | |
| Sumitomo Pharma America, INC. | $23.70 | 2025 | Gemtesa |
| Insightec,INC | $23.56 | 2023 | Exablate |
| Edwards Lifesciences Corporation | $23.28 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi-Aventis U.S. LLC | $22.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.90 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $17.92 | 2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $14.42 | 2025 | The Cologuard Plus Collection Kit |
| Inogen, INC. | $14.38 | 2021 | |
| Biogen, INC. | $13.15 | 2024 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Mansilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.